Jaguar Health, Inc. (JAGX)
JAGX Stock Price Chart
Explore Jaguar Health, Inc. interactive price chart. Choose custom timeframes to analyze JAGX price movements and trends.
JAGX Company Profile
Discover essential business fundamentals and corporate details for Jaguar Health, Inc. (JAGX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
12 May 2015
Employees
49.00
Website
https://jaguar.healthCEO
Lisa A. Conte
Description
Jaguar Health, Inc., a commercial-stage pharmaceutical firm, specializes in developing prescription therapies for both human and animal patients afflicted by gastrointestinal ailments, particularly chronic and severe diarrhea. Its operations are structured into two distinct divisions: Human Health and Animal Health. Presently, the company markets Mytesi, an approved medication providing symptomatic relief for noninfectious diarrhea experienced by adults with HIV/AIDS undergoing antiretroviral therapy. Beyond its commercial product, Jaguar Health is actively advancing Crofelemer, the active pharmaceutical ingredient in Mytesi, for a broad spectrum of additional indications. These include managing diarrhea associated with cancer therapy, seeking orphan drug designation for symptomatic relief in infants and children with congenital diarrheal disorders, and for adult and pediatric patients suffering from short bowel syndrome with intestinal failure. Further potential applications encompass supportive care for diarrhea linked to inflammatory bowel diseases, diarrhea-predominant irritable bowel syndrome (IBS-D), and idiopathic or functional diarrhea. Their pipeline also features lechlemer, a next-generation anti-secretory agent being developed to combat cholera. In the animal health sector, they are developing Canalevia, an oral, plant-derived drug candidate designed to address chemotherapy-induced diarrhea and exercise-induced diarrhea in canines. Established in 2013, Jaguar Health, Inc. maintains its headquarters in San Francisco, California.
JAGX Financial Timeline
Browse a chronological timeline of Jaguar Health, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 13 Aug 2026
EPS estimate is -$52.15, while revenue estimate is $4.24m.
Earnings released on 20 May 2026
EPS came in at -$13.60 surpassing the estimated -$149.10 by +90.88%, while revenue for the quarter reached $3.24m , missing expectations by -23.16%.
Stock split effective on 30 Apr 2026
Shares were split 1 : 35 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 30 Mar 2026
EPS came in at -$13.60 surpassing the estimated -$71.40 by +80.95%, while revenue for the quarter reached $2.03m , missing expectations by -44.76%.
Earnings released on 14 Nov 2025
EPS came in at -$6.28 falling short of the estimated -$5.08 by -23.62%, while revenue for the quarter reached $3.08m , missing expectations by -17.35%.
Earnings released on 14 Aug 2025
EPS came in at -$10.26 falling short of the estimated -$7.13 by -43.90%, while revenue for the quarter reached $2.98m , missing expectations by -8.90%.
Earnings released on 15 May 2025
EPS came in at -$16.70 falling short of the estimated -$10.82 by -54.34%, while revenue for the quarter reached $2.21m , missing expectations by -21.49%.
Earnings released on 31 Mar 2025
EPS came in at -$14.72 surpassing the estimated -$18.50 by +20.43%, while revenue for the quarter reached $3.50m , beating expectations by +12.90%.
Stock split effective on 24 Mar 2025
Shares were split 1 : 25 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 13 Nov 2024
EPS came in at -$26.25 surpassing the estimated -$59.25 by +55.70%, while revenue for the quarter reached $3.07m , missing expectations by -21.36%.
Earnings released on 13 Aug 2024
EPS came in at -$1.01 falling short of the estimated -$0.30 by -235.49%, while revenue for the quarter reached $2.72m , missing expectations by -20.00%.
Stock split effective on 23 May 2024
Shares were split 1 : 60 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 14 May 2024
EPS came in at -$0.90 falling short of the estimated -$0.45 by -100.00%, while revenue for the quarter reached $2.35m , missing expectations by -21.63%.
Earnings released on 1 Apr 2024
EPS came in at -$21.00 falling short of the estimated -$14.70 by -42.86%, while revenue for the quarter reached $2.30m , missing expectations by -11.88%.
Earnings released on 13 Nov 2023
EPS came in at -$5.72 surpassing the estimated -$18.45 by +68.98%, while revenue for the quarter reached $2.81m , beating expectations by +14.35%.
Earnings released on 14 Aug 2023
EPS came in at -$6.33 surpassing the estimated -$22.95 by +72.44%, while revenue for the quarter reached $2.68m , beating expectations by +17.37%.
Earnings released on 15 May 2023
EPS came in at -$35.99 surpassing the estimated -$67.50 by +46.68%, while revenue for the quarter reached $1.97m , missing expectations by -49.44%.
Earnings released on 27 Mar 2023
EPS came in at -$7.09 falling short of the estimated -$5.85 by -21.23%, while revenue for the quarter reached $3.30m , beating expectations by +65.00%.
Stock split effective on 23 Jan 2023
Shares were split 1 : 75 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 14 Nov 2022
EPS came in at -$5.40 falling short of the estimated -$3.38 by -60.00%, while revenue for the quarter reached $3.15m , missing expectations by -11.27%.
Earnings released on 22 Aug 2022
EPS came in at -$135.88 falling short of the estimated -$9.90 by -1.27k%, while revenue for the quarter reached $2.92m , missing expectations by -5.77%.
Earnings released on 10 May 2022
EPS came in at -$452.94 falling short of the estimated -$0.13 by -345.00k%, while revenue for the quarter reached $2.63m , beating expectations by +64.06%.
Earnings released on 11 Mar 2022
EPS came in at -$351.03 falling short of the estimated -$0.07 by -519.94k%, while revenue for the quarter reached $2.09m , missing expectations by -75.12%.
Earnings released on 17 Nov 2021
EPS came in at -$305.73 falling short of the estimated -$0.13 by -239.69k%, while revenue for the quarter reached $630.00k , missing expectations by -77.26%.
Stock split effective on 8 Sept 2021
Shares were split 1 : 3 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 13 Aug 2021
EPS came in at -$339.74 falling short of the estimated -$0.03 by -1.13m%, while revenue for the quarter reached $385.00k , meeting expectations.
JAGX Stock Performance
Access detailed JAGX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
